TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PGL4001 Versus Placebo in Uterine Myomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be a pre-menopausal woman between 18 and 50 years inclusive.~* Have excessive uterine bleeding due to myoma.~* Have a myoma-related anaemia.~* Have a myomatous uterus with at least one myoma of ≥ 3 cm diameter in size.~* Be eligible for one surgical procedure: e.g. hysterectomy, myomectomy or others.~* If of childbearing potential the subject must be practicing a non-hormonal method of contraception.~* Have a Body Mass Index (BMI) ≥ 18 and ≤ 40.~Exclusion Criteria:~* Has a history of or current uterine, cervical, ovarian or breast cancer.~* Has a history of or current endometrium atypical hyperplasia.~* Has a known severe coagulation disorder.~* Has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM) or a GnRH-agonist.~* Has abnormal hepatic function at study entry.~* Has a positive pregnancy test at baseline or is nursing or planning a pregnancy during the course of the study.~* Has a current (within twelve months) problem with alcohol or drug abuse.~* Is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- A (PGL4001 5mg) (Type: EXPERIMENTAL): PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
- B (PGL4001 10mg) (Type: EXPERIMENTAL): PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
- C (placebo) (Type: PLACEBO_COMPARATOR): PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CYP2B6 Polymorphisms in Methadone Disposition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Each subject must meet all of the following criteria:~* 18-50 yr old~* CYP2B6\*1/\*1, CYP2B6\*1/\*6 or CYP2B6\*6/\*6 genotype~* Good general health with no remarkable medical conditions~* BMI \< 33~* Provided informed consent~Exclusion Criteria:~Subjects will not be enrolled if any of the following criteria exist:~* Known history of liver or kidney disease~* Use of prescription or non prescription medications, herbals or foods known to be metabolized by or affect CYP2B6~* Females who are pregnant or nursing~* Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)~* Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Methadone arm (Type: EXPERIMENTAL): 1. Intravenous racemic methadone HCl, 6.0 mg bolus~2. Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM who are treated with metformin and/or diet and exercise~* HbA1c greater than or equal to 7% and less than or equal to 10.5%~* Total body weight \>50 kg (110 lb) with BMI 24.5 to 45.4 kg/m\^2~Exclusion Criteria:~* Any condition possibly affecting drug absorption~* Diagnosis of Type 1 diabetes~* History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months of screening~* Any malignancy not considered cured~* Personal or family history of MTC or MEN2, or participants with suspected MTC~* Acute pancreatitis or history of chronic pancreatitis~* Symptomatic gallbladder disease~* Known medical history of active proliferative retinopathy and/or macular edema~* Known medical history of active liver disease, including chronic active hepatitis B or C, or primary biliary cirrhosis~* Known history of HIV~* Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)~* Clinically relevant ECG abnormalities~* Positive urine drug test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-06882961 2.5 milligrams (mg) (Type: EXPERIMENTAL): None
- PF-06882961 10 mg (Type: EXPERIMENTAL): None
- PF-06882961 40 mg (Type: EXPERIMENTAL): Participants will be titrated up to 2 weeks to reach desired dose level
- PF-06882961 80 mg (Type: EXPERIMENTAL): Participants will be titrated up to 4 weeks to reach desired dose level
- PF-06882961 120 mg (Type: EXPERIMENTAL): Participants will be titrated up to 6 weeks to reach desired dose level

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adult (≥18 years old) hospitalized patients with respiratory tract diseases and abnormal mucus secretions such as: acute bronchitis, chronic bronchitis and exacerbations, emphysema, mucoviscidosis and bronchiectasis.~2. Chinese ethnicity and/or Chinese~3. Signed the informed consent form before any study-related procedure~4. Sputum viscosity score ≥ 2 at randomization visit~5. Expectoration difficulty score ≥ 2 at randomization visit~6. Willingness and ability to comply with study procedures~Exclusion Criteria:~1. Intolerance or contra-indication to treatment with NAC or ambroxol or allergy to any component of the study treatments~2. (For female patients) ongoing pregnancy or lactation, or childbearing potential but unwillingness to adopt abstinence or contraception measures during the study~3. Intake of an investigational drug within 1 month before the screening visit~4. Use of expectorants or drugs with expectorant effect within 2 days before randomization visit~5. Diagnosis of active tuberculosis, lung cancer, pulmonary fibrosis, acute pulmonary thromboembolism or any other respiratory condition that might, in the opinion of the investigator, compromise the safety of the patient or affect the interpretation of the results~6. Medical history of and/or illness (including laboratory abnormality) and/or treatment that in the investigator's opinion may interfere with the patient's safety, compliance, or study evaluations~7. Serum alanine aminotransferase and/or aspartate transaminase more than 3 times above the upper limit of normal at screening visit~8. Serum creatinine more than 3 times above the upper limit of normal at screening visit~9. Addiction to alcohol or drugs~10. Mental illness, or other reasons for non-cooperation in the investigator's opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active test treatment-NAC (Type: EXPERIMENTAL): NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
- Active control treatment-Ambroxol hydrochloride (Type: ACTIVE_COMPARATOR): Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 75 years of age , with ≥ 40 Kg~* Histological or cytological confirmed metastatic colorectal cancer~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Failed 2 or more lines of chemotherapy~* Adequate hepatic, renal, heart, and hematologic functions~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Signed and dated informed consent.~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure~Exclusion Criteria:~* Pregnant or lactating women~* Any factors that influence the usage of oral administration~* Central nervous system (CNS) metastasis~* One of the following conditions: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure~* Abuse of alcohol or drugs~* Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR inhibition~* Disability of serious uncontrolled intercurrence infection~* Proteinuria ≥ 2+ (1.0g/24hr)~* Evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness~* History of artery/venous thromboembolic events in 12 months, such as cerebral vascular accident (including transient ischemic attack) etc.~* History of acute myocardial infarction, acute coronary syndrome or coronary artery bypass graft (CABG) in 6 months~* Bone fracture or wounds that was not cured for a long time~* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: ACTIVE_COMPARATOR): treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
- control arm (Type: PLACEBO_COMPARATOR): control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18-75~2. HIV+~3. Clinically significant fatigue (score of 4.5+ on Fatigue Severity Scale, plus impairment on 1+ categories of Role Function Scale)~4. Fatigue duration for 3+ months~5. English-speaking~6. Able to give informed consent~7. Fecund women uses barrier method of contraception~Exclusion Criteria:~1. Primary care doctor does not approve of study participation~2. Unstable medical condition (e.g. liver failure; cirrhosis, new onset opportunistic infection in past month)~3. Untreated hypogonadism, except for men for whom testosterone replacement is medically contraindicated (serum testosterone below the reference range)~4. Untreated hypothyroidism (Thyroid Stimulating Hormone over 5 IUI/mL)~5. Untreated and uncontrolled hypertension~6. Clinically significant anemia (hematocrit \<30%)~7. Started testosterone or nandrolone in past 6 weeks~8. Started or changed an antiretroviral regimen in past 4 weeks if fatigue predated the change; otherwise, started or changed regimen in past 2 months~9. Untreated or under-treated major depressive disorder~10. Started antidepressant medication within past 6 weeks~11. Substance abuse/dependence (past 4 months)~12. Regular and frequent cannabis use (\> twice/week regularly)~13. Currently clinically significant suicidal ideation or Hamilton Depression Scale (HAM-D) score \>24~14. History or current psychosis or bipolar disorder~15. Pregnant or breastfeeding~16. Significant untreated insomnia (score \>3 on HAM-D insomnia items)~17. Currently taking psychostimulant medication or past nonresponse to modafinil~18. Has no alternative viable antiretroviral regimen after the current one~19. Left ventricular hypertrophy; mitral valve prolapse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Armodafinil (Type: EXPERIMENTAL): Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Nosocomial or severe community-acquired pneumonia due to Methicillin-Resistant Staphylococcus aureus~* Must be mechanically ventilated in intensive care unit~Exclusion Criteria:~* Non-bacterial pneumonia, such as viral, fungal, tuberculosis infections~* Underlying respiratory condition: bronchiectasis, post-tuberculosis, chronic obstructive pulmonary disease or asthma~* Complicated pneumonia, such as empyema, parapneumonic effusion requiring chest tube or drainage~* Already or previous treated with intravenous vancomycin (Not pneumonia)~* Adverse reaction due to inhaled ventolin before treatment of aerosolized vancomycin~* Hypersensitivity of vancomycin or glycopeptide antibiotics~* Positive culture of Enterococcus in respiratory specimen~* Pregnant or Breast-feeding patient~* Immunocompromised hosts: more than 1mg/kg of corticosteroid users for more than 3 months, transplantation recipients, AIDS patients~* Another aerosolized antibiotics within 48 hours of study enrollment~* Not adherent to mechanical ventilation protocol of this study~* Not arterial line monitoring~* Vancomycin minimum inhibitory concentration \>= 2㎍/㎖ of cultured Staphylococcus aureus

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aerosolized Vancomycin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biological Therapy in Treating Patients With Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed completely resected T1 or Ta papillary tumors of the urinary bladder TaG2 greater than 2 relapses in 2 years TaG3 unifocal or multifocal Unifocal primary T1G2-3 after a histological tumor-free second resection If multiple/multifocal, worst stage and grade AND/OR Histologically and cytologically confirmed primary or secondary carcinoma in situ of the urinary bladder No persistent T1 disease in second resection No contracted bladder (bladder capacity less than 80 mL) or bladder irritation within past 5 years No urothelial carcinoma of the upper urinary tract or the urethra~PATIENT CHARACTERISTICS: Age: 18 to 90 Performance status: WHO 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Liver function no greater than 1.5 times upper limit of normal (ULN) Renal: Renal function no greater than 1.5 times ULN Other: Not pregnant or nursing Fertile patients must use effective contraception No other concurrent malignancies except basocellular carcinoma No congenital or acquired immunosuppression (e.g., HIV, leukemia, lymphoma, transplant recipient) No uncontrollable or untreated urinary tract infection No chronic recurring bacterial cystitis~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior BCG therapy Chemotherapy: At least 3 months since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 5 years since prior radiotherapy to the bladder Surgery: See Disease Characteristics Other: No prior tuberculostatic therapy No concurrent local antiseptics or antibiotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- BCG-Connaught (Type: ACTIVE_COMPARATOR): None
- BCG Onko-Tice (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathology confirmed biliary malignancy, including intrahepatic bile duct carcinoma, extrahepatic bile duct carcinoma, and gallbladder carcinoma.~* Age:18-75 years, male or female.~* The estimated survival period is more than 3 months.~* ECOG 0-1.~* There is at least one measurable lesion, according to the RECIST 1.1 standard.~* Patients has not been treated by oxaliplatin, gemcitabine and pd-1 / pd-l1 antibody.~* Patients who have been treated tegafur or capecitabine as adjuvant chemotherapy or first-line treatment may be selected.~Exclusion Criteria:~* There were concurrent malignant tumors, except for the cured skin basal cell carcinoma and cervical carcinoma in situ.~* Other drug clinical trials have been taken in four weeks.~* Patients with a history of central nervous system metastasis or central nervous system metastasis are known before the screening.~* Patients with a history of unstable angina.~* The urine routine indicated that the urine protein was greater than ++ and confirmed the 24-hour urine protein quantification \>1.0 g.~* Have used immune-targeted therapy drugs.~* The patient had received a liver transplant.~* Having a history of chronic autoimmune diseases such as systemic lupus erythematosus.~* Having a history of immunodeficiency, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SHR1210+GEMOX (Type: EXPERIMENTAL): This is a single arm trial. Participants will receive SHR1210 + GEMOX treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years old~2. Patients with histologically confirmed gastric adenocarcinoma, defined as locally advanced unresectable or metastatic or recurrent disease~3. Patients with at least one measurable lesion~4. ECOG performance status of 0,1 or 2~5. Patients with no prior chemotherapy and radiotherapy for metastatic disease (patients who have received and completed prior adjuvant chemotherapy at least 6 months prior to study enrollment may be enrolled into the study, prior taxane chemotherapy should be excluded)~6. Patients with physiological functions (bone marrow, heart, liver, kidney, etc.) meeting the following criteria: WBC \>4000/mm3, ANC \>1500/mm3, PLT \>100,000/mm3, Hb \>9.0g/dL, ALT\<3 times the ULN (\<5 times the ULN for liver metastasis cases), Total bilirubin \<1.5mg/dL, Creatinine \<the upper limit of normal~7. Accessible for treatment and follow-up~8. Give written informed consent~9. Women of child bearing potential must have a negative plasma or urine pregnancy test within 72 hours prior to start of the study medication~Exclusion Criteria:~1. Patients who received surgery within 14 days prior to enrollment~2. Patients with CNS metastasis~3. History of hypersensitivity related to the administration of polyoxyethylated-castor-oil (cremophor EL)-containing preparation (e.g. cyclosporin,etc.) or hardened-castor-oil-containing preparation (e.g. vitamin preparation for injection,etc.)~4. Patients with a history of severe hypersensitivity~5. Active infectious symptoms~6. Patients with active gastrointestinal bleeding, intestinal obstruction or other situation that dose not allow oral intake of medication~7. Patients with ascites that adversely affects performance status~8. Pre-existing CTC Grade 2 or greater neuropathy (motor or sensory)~9. Pregnant or nursing females~10. Patients who have participated in other clinical trials within 30 days prior to the first dose of the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete